Last reviewed · How we verify
Gonyautoxins
Gonyautoxins is a Small molecule drug developed by maximiliano barahona vasquez. It is currently in Phase 3 development.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Gonyautoxins |
|---|---|
| Sponsor | maximiliano barahona vasquez |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy (PHASE1, PHASE2)
- Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study (PHASE1, PHASE2)
- NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects (PHASE1)
- Gonyautoxins Local Periarticular Injection for Pain Management After Total Knee Arthroplasty (PHASE3)
- Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles (PHASE1, PHASE2)
- Gonyautoxin in the Treatment of Chronic Tension-Type Headache (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gonyautoxins CI brief — competitive landscape report
- Gonyautoxins updates RSS · CI watch RSS
- maximiliano barahona vasquez portfolio CI
Frequently asked questions about Gonyautoxins
What is Gonyautoxins?
Who makes Gonyautoxins?
What development phase is Gonyautoxins in?
Related
- Manufacturer: maximiliano barahona vasquez — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing